Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.
about
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
P2860
Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Measurement properties of a pa ...... asis symptoms and signs diary.
@en
Measurement properties of a pa ...... asis symptoms and signs diary.
@nl
type
label
Measurement properties of a pa ...... asis symptoms and signs diary.
@en
Measurement properties of a pa ...... asis symptoms and signs diary.
@nl
prefLabel
Measurement properties of a pa ...... asis symptoms and signs diary.
@en
Measurement properties of a pa ...... asis symptoms and signs diary.
@nl
P2093
P2860
P1476
Measurement properties of a pa ...... asis symptoms and signs diary.
@en
P2093
Chenglong Han
Hilary H Colwell
Kelly McQuarrie
Steven R Feldman
Susan D Mathias
P2860
P304
P356
10.3109/09546634.2015.1114567
P577
2015-12-04T00:00:00Z